论文部分内容阅读
目的:探讨三子平喘颗粒用于儿童喘息性呼吸道感染的临床疗效。方法:选择喘息性呼吸道感染患儿105例,随机分为A、B两组。A组52例接受西医常规综合治疗,B组53例在A组基础上加服三子平喘颗粒治疗。连续治疗7天,对比两组患儿有效性和安全性。结果:B组患儿症状缓解时间、住院时间均明显短于A组,差异具有统计学意义(P<0.05)。两组患儿治疗期间均未见明显的不良反应,组间差异无统计学意义(P>0.05)。结论:三子平喘颗粒在儿童喘息性呼吸道感染的治疗中具有一定的辅助治疗效果,且无明显不良反应,值得临床推广应用。
Objective: To investigate the clinical efficacy of Sanzi Pingchuan Granule in children with wheezy respiratory infection. Methods: 105 children with wheezing respiratory tract infection were randomly divided into A and B groups. Fifty-two patients in group A received general western medicine treatment, and 53 in group B received Sanzi Pingchuan Granule treatment on the basis of group A. Continuous treatment for 7 days, compared two groups of children effectiveness and safety. Results: The symptom relief time and hospitalization time in group B were significantly shorter than that in group A, the difference was statistically significant (P <0.05). No significant adverse reactions were observed in both groups during treatment, with no significant difference between the two groups (P> 0.05). Conclusion: Sanzi Pingchuan Granules in children with asthmatic respiratory tract infection in the treatment of some adjuvant treatment, and no significant adverse reactions, it is worth promoting the clinical application.